Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Enoxacin-d8 is intended for use as an internal standard for the quantification of enoxacin (Item No. 16956) by GC- or LC-MS. Enoxacin is a fluoroquinolone antibiotic.1,2,3,4 It is active against clinical isolates of a variety of Gram-positive and Gram-negative bacteria, including S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens (MIC50s = 1, 0.12, 0.25, 0.5, and 1 mg/L, respectively).1 Enoxacin inhibits S. aureus DNA gyrase supercoiling activity and topoisomerase IV DNA decatenation (IC50s = 126 and 26.5 µg/ml, respectively).2 It increases survival in mouse models of systemic S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens infection with ED50 values of 15.1, 2.2, 4.1, 120.3, and 7.6 mg/kg, respectively.3 Enoxacin (4 and 8 mg/kg per day) also reduces tumor growth in a 143B human osteosarcoma mouse xenograft model.4 Formulations containing enoxacin have previously been used in the treatment of urinary tract infections and gonorrhea.
WARNING This product is not for human or veterinary use.
1. In-
2. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45(12), 3544-3547 (2001).
3. In vivo evaluation of NM441, a new thiazeto-
4. Enoxacin inhibits proliferation and invasion of human osteosarcoma cells and reduces bone tumour volume in a murine xenograft model. Oncol. Lett. 20(2), 1400-1408 (2020).